MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

被引：1
|
作者：
Ghobrial, Irene M. [1 ,2 ]
Siegel, David [3 ]
Vij, Ravi [4 ]
Wolf, Jeffrey L. [5 ]
Berdeja, Jesus G. [6 ]
Matous, Jeffrey V. [7 ]
Lipman, Peter [8 ]
Patel, Chirag [8 ]
Le, Trinh [9 ]
Rommel, Christian [9 ]
Berk, Gregory [8 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA
[3] Hackensack Univ Med Ctr, Hackensack, NJ USA
[4] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Colorado Blood Canc Inst, Denver, CO USA
[8] Millennium Pharmaceut Inc, Cambridge, MA USA
[9] Intellikine LLC, La Jolla, CA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4038.4038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4038
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
    Ghobrial, Irene M.
    Siegel, David S.
    Vij, Ravi
    Berdeja, Jesus G.
    Richardson, Paul G.
    Neuwirth, Rachel
    Patel, Chirag G.
    Zohren, Fabian
    Wolf, Jeffrey L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (04) : 400 - 405
  • [2] MLN4924, A NOVEL NAE INHIBITOR IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL): PHASE 1 DOSE-ESCALATION STUDY
    Shah, J.
    Jakubowiak, A.
    O'Connor, O.
    Orlowski, R.
    Patterson, M.
    Harvey, D.
    Berger, A.
    McDonald, A.
    Mulligan, G.
    Boral, A.
    Pickard, M.
    Smith, P.
    Kuan, H.
    Walker, R.
    Garnsey, J.
    Burke, K.
    Lonial, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 160 - 160
  • [3] Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
    Richardson, Paul G.
    Baz, Rachid
    Wang, Luhua
    Jakubowiak, Andrzej J.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandri
    Hui, Ai-Min
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 140 - 140
  • [4] Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
    Kumar, Shaji
    Bensinger, William I.
    Reeder, Craig B.
    Zimmerman, Todd M.
    Berenson, James R.
    Berg, Deborah
    Liu, Guohui
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Niesvizky, Ruben
    BLOOD, 2011, 118 (21) : 371 - 372
  • [5] MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study
    Assouline, Sarit
    Chang, Julie
    Rifkin, Robert
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Xi, Yingmei
    Di Bacco, Alessandra
    Martin, Peter
    BLOOD, 2011, 118 (21) : 1148 - 1148
  • [6] Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Shah, Jatin J.
    Jakubowiak, Andrzej J.
    O'Connor, Owen A.
    Orlowski, Robert Z.
    Patterson, Molly
    Harvey, Donald
    Berger, Allison J.
    McDonald, Alice
    Mulligan, George
    Petruzzelli, Lilli
    Pickard, Michael D.
    Smith, Peter G.
    Venkatakrishnan, Karthik
    Lonial, Sagar
    BLOOD, 2009, 114 (22) : 735 - 736
  • [7] A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies
    Infante, Jeffrey R.
    Tabernero, Josep
    Cervantes, Andres
    Jalal, Shadia
    Burris, Howard A.
    Macarulla, Teresa
    Perez-Fidalgo, J. Alejandro
    Neuwirth, Rachel
    Patel, Chirag
    Gangolli, Esha
    Brake, Rachael
    Sturm, Jeffrey
    Westin, Eric H.
    Gordon, Michael
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] ONCE-WEEKLY MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA: RESULTS OF A PHASE 1 DOSE-ESCALATION STUDY
    Assouline, S.
    Chang, J.
    Rifkin, R.
    Hui, A-M
    Gupta, N.
    Yu, J.
    Di Bacco, A.
    Shou, Y.
    Martin, P.
    HAEMATOLOGICA, 2012, 97 : 434 - 434
  • [9] Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
    Assouline, Sarit
    Chang, Julie E.
    Cheson, Bruce D.
    Rifkin, Robert
    Hamburg, Solomon
    Reyes, Ruben
    Hui, Ai-Min
    Yu, Jiang
    Gupta, Neeraj
    Di Bacco, Alessandra
    Shou, Yaping
    Martin, Peter
    BLOOD, 2012, 120 (21)
  • [10] Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma
    Shah, Jatin J.
    Harvey, R. Donald
    O'Connor, Owen A.
    Jakubowiak, Andrzej J.
    Smith, Mitchell R.
    Orlowski, Robert Z.
    Mulligan, George J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Lonial, Sagar
    BLOOD, 2010, 116 (21) : 1155 - 1155
12345